Is It Time To Reassess Genscript Biotech (SEHK:1548) After Its Recent Share Price Recovery?

• If you are wondering whether Genscript Biotech at HK$13.85 is priced for opportunity or already reflecting the story, this valuation breakdown is designed to give you a clear starting point.
• The stock has returned 0.7% over the last 7 days, 25.8% over the last 30 days, 8.3% year to date, and 25.2% over 1 year, while the 3 year and 5 year returns sit at 32.8% and 23.1% declines respectively.
• These mixed returns mean context really matters. Recent company updates, financing decisions, partnerships or regulatory developments can help explain why sentiment has shifted over different time frames. Understanding what has been driving attention toward Genscript Biotech, whether optimism or caution, can make a big difference to how you interpret the current share price.
• On Simply Wall St's framework, Genscript Biotech currently scores 6 out of 6 on valuation checks. The sections ahead walk through the standard valuation methods used to reach that result before finishing with a more complete way to think about what the stock could be worth.

Find out why Genscript Biotech's 25.2% return over the last year is lagging behind its peers.

Approach 1: Genscript Biotech Discounted Cash Flow (DCF) Analysis

A Discounted Cash Flow, or DCF, model estimates what a company could be worth by projecting its future cash flows and then discounting those back to today’s value.

For Genscript Biotech, the model used is a 2 Stage Free Cash Flow to Equity approach. The latest twelve month free cash flow sits at about $81.65 million. Analysts provide specific forecasts for the coming years, and Simply Wall St then extends those projections, with the ten year outlook including an estimated free cash flow of $526.52 million in 2035.

Aggregating and discounting these projected cash flows results in an estimated intrinsic value of about HK$25.09 per share. Compared with the current share price of HK$13.85, the DCF output suggests the shares trade at a 44.8% discount.

Result: UNDERVALUED

Our Discounted Cash Flow (DCF) analysis suggests Genscript Biotech is undervalued by 44.8%. Track this in your watchlist or portfolio, or discover 228 more high quality undervalued stocks.

Head to the Valuation section of our Company Report for more details on how we arrive at this Fair Value for Genscript Biotech.

Approach 2: Genscript Biotech Price vs Sales

For companies where earnings may not fully capture the business, the P/S ratio is often a helpful cross check, because it compares what the market is paying for each unit of revenue.

In general, higher growth expectations or lower perceived risk can justify a higher "normal" P/S multiple, while slower growth or higher uncertainty can point to a lower one. That is why it helps to look at a few benchmarks rather than the headline number in isolation.

Genscript Biotech currently trades on a P/S ratio of 4.03x. This sits close to the Life Sciences industry average P/S of 3.85x and well below the peer group average of 13.79x. Simply Wall St also calculates a proprietary "Fair Ratio" for Genscript Biotech of 4.50x, which reflects factors such as the company’s growth profile, risk characteristics, profit margins, industry and market cap.

This Fair Ratio is more tailored than a simple comparison with peers or the broad industry, because it adjusts for business quality and risk rather than assuming every company deserves the same multiple. With Genscript Biotech at 4.03x versus a Fair Ratio of 4.50x, the P/S check points to the shares trading below that customised benchmark.

Result: UNDERVALUED

P/S ratios tell one story, but what if the real opportunity lies elsewhere? Start investing in legacies, not executives. Discover our 95 top founder-led companies.

Upgrade Your Decision Making: Choose your Genscript Biotech Narrative

Earlier it was mentioned that there is an even better way to understand valuation. Narratives on Simply Wall St let you attach a clear story to your numbers by linking your view of Genscript Biotech’s future revenue, earnings and margins to a forecast, a Fair Value, and then comparing that Fair Value with the current share price to help you decide if and when to act.

Available on the Community page and used by millions of investors, Narratives are kept current as fresh news or earnings are released. They make it easy to see how one investor might lean toward the higher HK$21.01 fair value with a story built around European mRNA expansion and AI enabled efficiency, while another might anchor closer to HK$15.88 with more weight on competition, automation costs and reliance on key subsidiaries.

Do you think there's more to the story for Genscript Biotech? Head over to our Community to see what others are saying!

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com